Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.

Abstract

We describe the case of a 51-year-old patient with relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation (BMT), who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) after conditioning with a novel regimen consisting of fludarabine, busulfan, and antithymocyte globulin. The second PBSCT was performed early, at 3 months after the initial allogeneic BMT, but it was well tolerated and complete hematologic remission was documented. The patient did not experience any early transplantation-related organ toxicity but died from opportunistic infection 6 months after the second transplantation. Our experience suggests that this novel regimen may induce remission and could be offered to patients relapsing after the first transplantation; however, the fludarabine-containing regimen might be accompanied by profound immunosuppression.

• Authors: N Kono, K Ohashi, E Sasaki, Y Okoshi, D Mizuchi, S Mori, H Akiyama, K Karasawa, H Kaku, R Okamoto, Y Maeda, T Sasaki, Y Okuyama, K Hiruma, H Sakamaki
• Journal: International journal of hematology (Int J Hematol) Vol. 73 Issue 1 Pg. 122-5 (Jan 2001) ISSN: 0925-5710 [Print] Japan
• PMID: 11372748 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Vidarabine
• fludarabine

Topics

• Antineoplastic Agents (administration & dosage, toxicity)
• Bone Marrow Transplantation
• Fatal Outcome
• Hematopoietic Stem Cell Transplantation (adverse effects, methods)
• Humans
• Infections (etiology)
• Male
• Middle Aged
• Myelodysplastic Syndromes (complications, therapy)
• Recurrence
• Transplantation Conditioning (adverse effects, methods)
• Transplantation, Homologous (adverse effects, methods)
• Vidarabine (administration & dosage, analogs & derivatives, toxicity)